Core Insights - AVITA Medical reported financial results for Q4 and full year 2025, indicating a year of stabilization and a shift towards execution-focused growth in 2026 [1][4]. Fourth Quarter 2025 Financial Highlights - Total revenue for Q4 2025 was $17.6 million, a decrease of 4% from $18.4 million in Q4 2024, primarily due to reimbursement headwinds [6][7]. - Gross profit margin was 81.2%, down from 87.6% in Q4 2024, influenced by product mix and inventory adjustments [8]. - Operating expenses decreased by 5% to $24.7 million compared to $26.1 million in Q4 2024, reflecting a lower cost base [9]. - Net loss for Q4 2025 was $11.6 million, or a loss of $0.38 per share, compared to a loss of $11.6 million, or $0.44 per share in Q4 2024 [12]. Full-Year 2025 Financial Highlights - Total revenues for 2025 increased by 11% to $71.6 million from $64.3 million in 2024, driven by deeper penetration in customer accounts and new product launches [13]. - Gross profit margin for the full year was 82.1%, down from 85.8% in 2024, primarily due to product mix and higher inventory reserves [14]. - Total operating expenses for 2025 were $101.4 million, a decrease of 9% from $111.8 million in the prior year [15]. - Net loss for the full year was $48.6 million, or a loss of $1.74 per share, compared to a net loss of $61.8 million, or $2.39 per share in 2024 [16]. Business Updates and Future Guidance - The company expects full-year 2026 revenue in the range of $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [5]. - In January 2026, the company refinanced its existing debt under a new credit facility with Perceptive Advisors, securing up to $60 million to strengthen its capital structure [17][18]. - As of January 2026, six of the seven Medicare Administrative Contractors have published payment rates for RECELL, alleviating a key constraint on utilization experienced in 2025 [6]. - The company is focused on disciplined cash management and accelerating commercial momentum across its core U.S. burn and trauma center opportunities [19].

Core Insights - AVITA Medical, Inc. will report its third quarter 2025 financial results on November 6, 2025, after U.S. market close [1] - A conference call and webcast will be held on the same day to discuss financial results and business highlights [1] Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions [3] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [3] - In the U.S., AVITA Medical also has rights to manufacture and exclusively market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3] International Market Presence - The RECELL System is approved for various applications in international markets, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4]

Financial Results - Commercial revenue for Q2 2025 was $18.4 million, representing a 21% increase compared to $15.2 million in Q2 2024 [8][12] - Net loss for Q2 2025 improved to $9.9 million, or a loss of $0.38 per share, compared to a net loss of $15.4 million, or a loss of $0.60 per share in Q2 2024 [8][16] - Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses [8][14] Business Update - Demand for RECELL was dampened in the first half of 2025 due to delays in provider payments, leading to a backlog of unpaid claims [6][9] - The Centers for Medicare and Medicaid Services (CMS) approved New Technology Add-on Payment (NTAP) for the RECELL System for inpatient trauma wounds [8][10] - AVITA anticipates recovery in RECELL demand in the second half of 2025 as claims backlog is resolved [10] Clinical Highlights - RECELL reduces hospital stays by 36% based on real-world analysis from the national burn registry over five years [5][8] - Cohealyx achieves autograft readiness in as little as five days, with first clinical results published [8] Strategic Developments - The company amended credit terms with OrbiMed, lowering revenue covenants and issuing common stock in lieu of cash payment [8][11] - Michael Tarnoff, MD, FACS, was appointed to the Board of Directors, bringing extensive healthcare leadership experience [8] Guidance Adjustments - Full-year 2025 revenue guidance was revised to a range of $76 million to $81 million, down from previous guidance of $100 million to $106 million [11][15] - The company expects to reach cash flow break-even in Q2 2026 and GAAP profitability in Q3 2026, later than previously anticipated [11][15]

Core Insights - AVITA Medical, Inc. has appointed Dr. Michael Tarnoff as a non-executive Director to its Board of Directors, effective August 6, 2025, to enhance its focus on patient-centric wound-healing technologies [1][2] - The company has also announced the resignation of Lou Panaccio as Board Chair, with Cary Vance elected to take over the position effective August 7, 2025 [2][3] Company Developments - Dr. Tarnoff's extensive experience includes 23 years at Tufts Medical Center and leadership roles at Medtronic and Covidien, which will contribute to AVITA's growth in therapeutic acute wound care [4][7] - Cary Vance, with over 25 years of executive leadership in the healthcare industry, is expected to drive innovation and support the company's mission [5][7] Product and Technology Focus - AVITA Medical specializes in therapeutic acute wound care, with its flagship product, the RECELL System, designed to optimize wound healing and accelerate patient recovery [6][8] - The RECELL System is FDA-approved for treating thermal burn wounds and trauma wounds, utilizing a patient's own skin to create Spray-On Skin Cells [6][8]